Cyberonics’ Sharpened Focus Buoys Stock 13% In May; OTC Index Off 2.6%
This article was originally published in The Gray Sheet
Cyberonics' revised NCP vagus nerve stimulation development plan for depression, combined with a sharper focus on epilepsy and fiscal fourth-quarter performance ahead of Wall Street expectations, led to a 12.5% stock gain in May
You may also be interested in...
Cyberonics expects to scale-back its investment in developing a depression indication for its NeuroCybernetic Prosthesis vagus nerve stimulation system by 25% in fiscal 2003
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.